Varicella Zoster (HHV-3) Infections is an indication for drug development with over 70 pipeline drugs currently active. According to GlobalData, preregistered drugs for Varicella Zoster (HHV-3) Infections have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Varicella Zoster (HHV-3) Infections compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Varicella Zoster (HHV-3) Infections overview
Varicella-zoster virus (VZV), also known as human herpesvirus 3 (HHV-3), causes two distinct infections: chickenpox (varicella) and shingles (herpes zoster). Varicella is a highly contagious viral infection characterized by an itchy rash with red spots and fluid-filled blisters that break open and form scabs. It spreads through respiratory droplets and direct contact with the rash. Varicella commonly affects children, and symptoms besides the rash include fever, fatigue, and loss of appetite. The illness usually resolves within 1-2 weeks. However, after the primary infection of chickenpox, VZV can remain dormant in nerve cells. Later in life or when the immune system weakens, the virus may reactivate, causing shingles. Shingles manifests as a painful rash that typically appears on one side of the body, often in a band-like pattern along a nerve pathway. Other symptoms may include burning, tingling, or shooting pain. It usually lasts for several weeks.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Varicella Zoster (HHV-3) Infections, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
